Last reviewed · How we verify
Edronax (REBOXETINE)
At a glance
| Generic name | REBOXETINE |
|---|---|
| Drug class | reboxetine |
| Target | Sodium-dependent noradrenaline transporter |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Major depressive disorder
Common side effects
Key clinical trials
- A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) (PHASE3)
- The Role of the Brain in Mental and Physical Fatigue (PHASE3)
- Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD (PHASE2)
- A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy (PHASE3)
- Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation (PHASE4)
- Reboxetine for Sleep Apnoea After ENT Surgery (PHASE2)
- Studying the Role of Brain Molecules for Decision Making (NA)
- Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |